Drugs / MBQ-167
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06075810 | Nov 2023 → Oct 2025 overdue | breast cancer | MBQ Pharma | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBQ-167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075810 ↗ |
| Action | Inhibit | “MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42” NCT06075810 ↗ |
| Modality | Small molecule | — CHEMBL5290216 ↗ |
| Route | Oral | “take MBQ-167 orally twice a day” NCT06075810 ↗ |
| Target | CDC42 | “MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42” NCT06075810 ↗ |